Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer

Completed · Not applicable

Conditions studied: Breast Cancer, Early Stage Estrogen Receptor (ER) Positive Breast Cancer

In brief

Investigators will examine the impact of the Breast Cancer Index (BCI) result on patients' anxiety / fear of recurrence and satisfaction with decisions regarding endocrine therapy.

Key facts

Study ID

NCT02057029

Run by

Yale University

People needed

96

Starts

2014-01-01

Expected to finish

2015-06-01

Last updated by the study team

2016-01-08

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Each patient must meet all of the following criteria in order to be considered for enrollment:
• Histologically confirmed ER positive, stage I-III breast cancer who have been treated with curative intent and completed at least four years of adjuvant endocrine therapy.
• Life expectancy ≥ 5 years.
• Must be able to provide informed consent.
• Willing to consider continuation of endocrine therapy beyond 5 years.

You may not qualify if…

• A patient must not be enrolled if any contraindication exists for extended adjuvant endocrine therapy as identified by the treating oncologist.

Where it is running

• Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.